PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18084318-7 2008 Celecoxib reduced activation of p38 and p55 c-Jun terminal NH(2) kinase (JNK) MAPKs, but did not affect p46 JNK or p42/44 MAPK phosphorylation. Celecoxib 0-9 mitogen-activated protein kinase 14 Homo sapiens 32-35 21220497-5 2011 Pharmacologic inhibition and siRNA silencing of p38-mitogen-activated protein kinase and the Sp1 transcription factor revealed their involvement in this celecoxib-induced VEGF expression. Celecoxib 153-162 mitogen-activated protein kinase 14 Homo sapiens 48-84 24627094-0 2014 Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2. Celecoxib 80-89 mitogen-activated protein kinase 14 Homo sapiens 119-122 24627094-7 2014 We demonstrated that sequential treatment with bortezomib and celecoxib induced apoptosis via p-p38-mediated G0/G1 cell cycle arrest and endoplasmic reticulum (ER) stress. Celecoxib 62-71 mitogen-activated protein kinase 14 Homo sapiens 96-99 18080123-4 2008 The inhibitors of NF-kappaB, JNK and p38, but not ERK, decreased IL-1beta-enhanced MMP-1, MMP-3 and NO production, respectively, and 100 nM celecoxib down-regulated the phosphorylation of NF-kappaB and JNK but has no effect on either p38 or ERK. Celecoxib 140-149 mitogen-activated protein kinase 14 Homo sapiens 234-237 18084318-11 2008 CONCLUSIONS AND IMPLICATIONS: Our findings show that celecoxib caused down-regulation of ICAM-1 and VCAM-1, affecting the adhesive properties of HT29 cells in a COX-2 independent way, inhibiting p38 and p55 MAPKs and activating a pro-apoptotic pathway. Celecoxib 53-62 mitogen-activated protein kinase 14 Homo sapiens 195-198 16169610-8 2006 G-Gly significantly reduced serum-starvation and celecoxib-induced apoptosis and this effect was also blocked by inhibition of the p38 MAP kinase, ERK and NF-kappaB pathways. Celecoxib 49-58 mitogen-activated protein kinase 14 Homo sapiens 131-134 17406816-10 2007 We conclude that leptin stimulates colon cancer proliferation via COX-independent pathways and reduces celecoxib-induced apoptosis via ERK, p38 MAP kinase, and NF-kappaB pathways. Celecoxib 103-112 mitogen-activated protein kinase 14 Homo sapiens 140-143 17540426-0 2007 Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Celecoxib 54-63 mitogen-activated protein kinase 14 Homo sapiens 14-50 17540426-8 2007 Celecoxib activated the phosphorylation of p38 mitogen-activated protein (MAP) kinase. Celecoxib 0-9 mitogen-activated protein kinase 14 Homo sapiens 43-46 17540426-10 2007 SB203580, a specific p38 MAP kinase inhibitor, protected the survivin protein expression and decreased the levels of gamma-H2AX and apoptosis in the celecoxib-exposed cells. Celecoxib 149-158 mitogen-activated protein kinase 14 Homo sapiens 21-24 17540426-12 2007 Our results provide for the first time that p38 MAP kinase participates in the down-regulation of survivin and subsequently induces the activation of gamma-H2AX for mediating apoptosis following treatment with celecoxib in human colorectal cancer cells. Celecoxib 210-219 mitogen-activated protein kinase 14 Homo sapiens 44-47 16949034-4 2006 Celecoxib increased p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and p70S6 kinase (p70S6K) phosphorylation while leaving JNK activation unaffected. Celecoxib 0-9 mitogen-activated protein kinase 14 Homo sapiens 20-34 16949034-4 2006 Celecoxib increased p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and p70S6 kinase (p70S6K) phosphorylation while leaving JNK activation unaffected. Celecoxib 0-9 mitogen-activated protein kinase 14 Homo sapiens 20-23 15990304-2 2005 The docking analysis revealed why celecoxib has a less favorable binding energy (DeltaG= -12.4kcal/mol) than the selective p38 MAP kinase (p38 MAPK) inhibitor, SB203580 (DeltaG= -22.2kcal/mol). Celecoxib 34-43 mitogen-activated protein kinase 14 Homo sapiens 123-137 15990304-2 2005 The docking analysis revealed why celecoxib has a less favorable binding energy (DeltaG= -12.4kcal/mol) than the selective p38 MAP kinase (p38 MAPK) inhibitor, SB203580 (DeltaG= -22.2kcal/mol). Celecoxib 34-43 mitogen-activated protein kinase 14 Homo sapiens 139-147 15990304-3 2005 The CoMFA results revealed unfavorable steric effects that can be related to the predicted lower p38 MAP kinase inhibitory activity of celecoxib. Celecoxib 135-144 mitogen-activated protein kinase 14 Homo sapiens 97-111 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Celecoxib 75-84 mitogen-activated protein kinase 14 Homo sapiens 120-123 15647833-5 2005 Celecoxib also decreased the phosphorylation state of p38 and p44/42 of MAP kinase. Celecoxib 0-9 mitogen-activated protein kinase 14 Homo sapiens 54-57 29031211-8 2017 Furthermore, we used Celecoxib as a positive control, and results showed that Cyanidin-3-O-glucoside was more effective at decreasing EGFR phosphorylation than Celecoxib, which translated into a stronger inhibitory effect against the downstream elements p38, ERK, and JNK. Celecoxib 160-169 mitogen-activated protein kinase 14 Homo sapiens 254-257